Cormorant Asset Management, LP Argenx Se Transaction History

Cormorant Asset Management, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $7.71 Million - $9.6 Million	-30,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $2.48 Million - $3.08 Million	-10,000 Reduced 25.0%	30,000 $8.82 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $6.47 Million - $8.18 Million	-30,000 Reduced 42.86%	40,000 $10.5 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $1.27 Million - $2.33 Million	-10,000 Reduced 12.5%	70,000 $15.8 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $2.18 Million - $3.3 Million	-20,000 Reduced 20.0%	80,000 $10.5 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $3 Million - $4.62 Million	-28,110 Reduced 21.94%	100,000 $16.1 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $2.48 Million - $3.29 Million	-21,890 Reduced 14.59%	128,110 $14.6 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $14.4 Million - $17.7 Million	-125,000 Reduced 45.45%	150,000 $21.2 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $17.3 Million - $23.6 Million	-175,000 Reduced 38.89%	275,000 $34.3 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $16.6 Million - $28.6 Million	260,000 Added 136.84%	450,000 $43.2 Million
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $6.68 Million - $8.56 Million	-88,536 Reduced 31.79%	190,000 $14.4 Million
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $652,874 - $976,618	-11,464 Reduced 3.95%	278,536 $22.4 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $6.55 Million - $18.4 Million	290,000	290,000 $18.3 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.